Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, USA.
Semin Oncol. 2011 Oct;38(5):673-81. doi: 10.1053/j.seminoncol.2011.07.001.
The myelodysplastic syndromes (MDS) are divided into lower-risk and higher-risk categories. This differentiation is important for treatment selection. Over the last decade, we have witnessed significant improvements in the treatment of patients with higher-risk MDS that have resulted in improved survival with the hypomethylating agent 5-azacytidine This has resulted in a shift from the use of acute myelogenous leukemia (AML)-like therapies, which were traditionally offered to this group of patients in the past, to the hypomethylating agents, which have become the standard of care. Despite these advances, new therapies or combinations are needed to improve response and survival rates. This review will summarize results from current available therapies and discuss potential needs and ongoing research in the area of treatment of higher-risk MDS.
骨髓增生异常综合征（MDS）分为低危和高危两类。这种区分对于治疗选择很重要。在过去的十年中，我们见证了高危 MDS 患者治疗的显著改善，这使得低甲基化药物 5-氮杂胞苷的治疗效果得到了改善，从而提高了生存率。这导致了治疗策略的转变，从过去传统用于该组患者的急性髓细胞白血病（AML）样疗法转变为低甲基化药物，后者已成为标准治疗方法。尽管取得了这些进展，但仍需要新的疗法或联合疗法来提高缓解率和生存率。这篇综述将总结目前可用疗法的结果，并讨论高危 MDS 治疗领域的潜在需求和正在进行的研究。
